DERMATA THERAPEUTICS, INC. Operating Cash Flow
DERMATA THERAPEUTICS, INC. (DRMA) reported Operating Cash Flow of -$4.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.42M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.48M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.37M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.80M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$11.16M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$6.41M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$8.83M.
- DERMATA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2021 was -$5.69M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.90M 10-Q · filed 2026-08-11 | -$6.27M derived: sum of 3 quarters · filed 2026-08-11 | -$8.08M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | -$2.48M 10-Q · filed 2026-05-13 | -$3.85M derived: sum of 2 quarters · filed 2026-08-11 | -$5.66M derived: sum of 3 quarters · filed 2026-08-11 | -$8.35M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | -$1.37M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-11 | -$3.18M derived: sum of 2 quarters · filed 2026-08-11 | -$5.87M derived: sum of 3 quarters · filed 2026-08-11 | -$7.80M 10-Q · filed 2026-08-11 | -$7.76M 10-K · filed 2026-03-26 | |
| 2025-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$4.49M derived: sum of 2 quarters · filed 2026-08-11 | -$6.43M 10-Q · filed 2025-11-14 | -$9.34M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | -$2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.62M 10-Q · filed 2026-08-11 | -$7.54M derived: sum of 3 quarters · filed 2026-08-11 | -$10.96M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$1.93M 10-Q · filed 2026-05-13 | -$4.85M derived: sum of 2 quarters · filed 2026-05-13 | -$8.27M derived: sum of 3 quarters · filed 2026-05-13 | -$10.39M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | -$2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$6.33M derived: sum of 2 quarters · filed 2026-03-26 | -$8.46M derived: sum of 3 quarters · filed 2026-03-26 | -$11.16M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | -$3.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$5.54M derived: sum of 2 quarters · filed 2025-11-14 | -$8.25M 10-Q · filed 2025-11-14 | -$9.40M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$4.83M 10-Q · filed 2025-08-13 | -$5.98M derived: sum of 3 quarters · filed 2025-08-13 | -$7.75M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | -$2.70M 10-Q · filed 2025-05-14 | -$3.85M derived: sum of 2 quarters · filed 2025-05-14 | -$5.62M derived: sum of 3 quarters · filed 2025-05-14 | -$7.46M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$2.92M derived: sum of 2 quarters · filed 2025-03-17 | -$4.76M derived: sum of 3 quarters · filed 2025-03-17 | -$6.41M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | -$1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$3.61M derived: sum of 2 quarters · filed 2024-11-13 | -$5.26M 10-Q · filed 2024-11-13 | -$7.09M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | -$1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$3.49M 10-Q · filed 2024-08-07 | -$5.32M derived: sum of 3 quarters · filed 2024-08-07 | -$7.88M derived: sum of 4 quarters · filed 2024-08-07 | ||
| 2023-03-31 | -$1.65M 10-Q · filed 2024-05-15 | -$3.48M derived: sum of 2 quarters · filed 2024-05-15 | -$6.04M derived: sum of 3 quarters · filed 2024-05-15 | -$7.88M derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | -$1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$4.39M derived: sum of 2 quarters · filed 2024-03-21 | -$6.23M derived: sum of 3 quarters · filed 2024-03-21 | -$8.83M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | -$2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$4.40M derived: sum of 2 quarters · filed 2023-11-09 | -$7.01M 10-Q · filed 2023-11-09 | -$8.81M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$4.45M 10-Q · filed 2023-08-10 | -$6.25M derived: sum of 3 quarters · filed 2023-08-10 | -$8.46M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | -$2.61M 10-Q · filed 2023-05-11 | -$4.41M derived: sum of 2 quarters · filed 2023-05-11 | -$6.62M derived: sum of 3 quarters · filed 2023-05-11 | -$7.53M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$4.01M derived: sum of 2 quarters · filed 2023-02-21 | -$4.92M derived: sum of 3 quarters · filed 2023-02-21 | -$5.69M 10-K · filed 2023-02-21 | ||
| 2021-09-30 | -$2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$3.11M derived: sum of 2 quarters · filed 2022-11-10 | -$3.89M 10-Q · filed 2022-11-10 | $3.89M 10-Q · filed 2021-11-15 | -$11.41M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$903.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$1.68M 10-Q · filed 2022-08-15 | -$9.20M derived: sum of 3 quarters · filed 2022-08-15 | -$3.59M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | -$776.22K 10-Q · filed 2022-05-16 | -$8.30M derived: sum of 2 quarters · filed 2022-05-16 | -$2.68M derived: sum of 3 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$1.91M derived: sum of 2 quarters · filed 2022-03-28 | -$4.03M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $5.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $3.49M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | -$2.12M 10-Q · filed 2021-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |